ascopubs.org

Apa-RP: Multicenter phase 2 study of apalutamide (Apa) and androgen deprivation therapy (ADT) for the treatment of high-risk localized prostate cancer (HR LPC) following ...

This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.
ascopubs.org

Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC ...

Apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer: A randomized trial (PERSIAN). This is an ASCO Meeting Abstract from the 2024 ASCO ...